期刊文献+

肝脏转运体介导药物相互作用的研究进展 被引量:10

Drug-drug interactions mediated by hepatic transporters
下载PDF
导出
摘要 转运体是位于细胞膜上的功能性膜蛋白,在肝脏表达广泛,其生理功能是将大多数内源性物质、外源性化学异物或药物等摄取进入肝脏,在肝脏经过一定的代谢转化,最终将其经胆汁排至肝外.肝脏转运体在药物肝胆转运中起重要作用,转运体与药物在肝脏的摄取、代谢及排泄等功能密切相关,转运体的功能抑制、缺失是生理疾病和药物之间相互作用的重要因素.临床联合应用与转运体有关的药物时可能发生由转运体介导的药物相互作用,如西立伐他汀不良反应事件.本文从肝脏转运体的抑制、诱导和单核苷酸多态性出发,对由肝脏转运体引起的药物相互作用作一综述. Transporters are a class of functional membrane proteins that are extensively expressed in the liver and are involved in the transport of a wide variety of compounds including endogenous and xenobiotic substances from the bloodstream into hepatocytes. And then, these parent sub stances are metabolized in the liver and excreted into bile. Hepatic transporters play important roles in the hepatic transport process of drugs, including the uptake of drugs from blood into hepatocytes or the effiux of drugs into bile. The uptake, metabolism and excretion of drugs in the liver are related to hepatic transporters. Decline or loss of transporting function of trans- porters caused by gene mutations is related with a variety of liver diseases. Drug-drug interaction may be induced when one drug (as a substrate or inhibitor of hepatic transporters) is co-admin-istered simultaneously with another in clinical practice, such as adverse events of cerivastatin. In this paper, we review the potential drug-drug interactions mediated by hepatic transporters.
出处 《世界华人消化杂志》 CAS 北大核心 2012年第28期2655-2660,共6页 World Chinese Journal of Digestology
基金 国家自然科学基金资助项目 No.81072694 大连市科委基金资助项目 No.2010E12SF060~~
关键词 肝脏转运体 药物相互作用 药代动力学 Hepatic transporters Drug-drug inter-action Pharmacokinetics
  • 相关文献

参考文献51

  • 1Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek- Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236. 被引量:1
  • 2Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 2010; 11:323-332. 被引量:1
  • 3奚忠,江春平,丁义涛.ABCG2在肝细胞性肝癌组织和肝癌细胞株中的表达及意义[J].世界华人消化杂志,2009,17(3):247-252. 被引量:7
  • 4孟强,刘克辛.转运体在肝脏中的作用[J].世界华人消化杂志,2011,19(9):881-886. 被引量:13
  • 5Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATPIBI: SLC21A6)-mediated hepatic uptake and CYP2C8- mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311:228-236. 被引量:1
  • 6Piorkowski JD. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". JAMA 2004; 292: 2655-2657; discussion 2658-2659. 被引量:1
  • 7张健,刘克辛.药物转运体介导的小肠吸收、肾脏排泄与药物相互作用的关系[J].药学学报,2010,45(9):1089-1094. 被引量:27
  • 8刘克辛.转运体介导的药物相互作用与临床安全用药[J].大连医科大学学报,2012,34(1):1-8. 被引量:12
  • 9Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. Role of organic anion-transporting poly- peptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 2003; 371: 897-905. 被引量:1
  • 10Cui Y, K0nig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 276:9626-9630. 被引量:1

二级参考文献66

  • 1Caecilia HC Sukowati,Natalia Rosso,Lory S Crocè,Claudio Tiribelli.Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma[J].World Journal of Hepatology,2010,2(3):114-126. 被引量:17
  • 2Jing Zhao,Bing-Yun Yu,Jin-E Yang,Key Laboratory of Gene Engineering of the Ministry of Education,School of Life Sciences,Sun Yat-sen (Zhongshan) University,Guangzhou 510275,Guangdong Province,China Dao-Yuan Wang,Department of Medical Oncology,The First Affiliated Hospital of Guangzhou Medical College,Guangzhou 510120,Guangdong Province,China.Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma[J].World Journal of Gastroenterology,2010,16(48):6104-6110. 被引量:8
  • 3王百林,杨海燕,翟淑萍,陈孝平,仲永,张庆业,孟磊.多药耐药相关蛋白基因、肺耐药蛋白基因在肝细胞癌中的表达及临床意义[J].中国普通外科杂志,2005,14(2):95-99. 被引量:11
  • 4Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp ivied 1996; 183:1797-1806. 被引量:1
  • 5Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034. 被引量:1
  • 6Seigel GM, Campbell LM, Narayan M, Gonzalez- Fernandez F. Cancer stern cell characteristics in retinoblastoma. Mol Vis 2005; 11:729-737. 被引量:1
  • 7Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007; 6:92-97. 被引量:1
  • 8Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH.Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 2007; 67:3716-3724. 被引量:1
  • 9Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24:506-513. 被引量:1
  • 10Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44:240-251. 被引量:1

共引文献77

同被引文献122

  • 1刘友生,晏良遂,傅国金,李爱莲.烧伤后肠源性标记内毒素在主要内脏器官的分布及肝脏亚细胞定位[J].中华创伤杂志,1995,11(3):166-168. 被引量:1
  • 2李小林,朱心强.胆汁酸代谢相关核受体的研究进展[J].中国药理学与毒理学杂志,2007,21(2):152-156. 被引量:8
  • 3刘春海,杨华生,李超.HPLC法测定复方连芍片中盐酸小檗碱的含量[J].中华中医药学刊,2007,25(9):1959-1960. 被引量:1
  • 4邓中甲.方剂学[M]北京:中国中医药出版社,2010108. 被引量:1
  • 5Rbee SH. Lipopolysaecharide: basic biochemistry, intraeellular signaling, and physiological impacts in the gut [ J ]. lntest Res, 2014,12(2) :90 -95. 被引量:1
  • 6Yi H, An Y, Lv H, et al. The association of lipopolysaccharide and inflammatory factors with hepatoputmonary syndrome and their changes after orthotopic liver transplantation [ J 1. J Thorac Dis, 2014,6(10) :1469 - 1475. 被引量:1
  • 7Pannee C, Chandhanee I, Wacharee L. Antiinflammatory effects of essential oil from the leaves of Cinnamomum cassia and cinnamal- dehyde on lipopolysaccharide-stimulated J774A. 1 cells [ J 1. J Adv Pharm Technol Res,2014,5 (4) : 164 - 170. 被引量:1
  • 8International Transporter Consortium, Giacomini KM, Huang SM, et al. Membrane transporters in drug development [ J 1. Nat Rev Drug Diseov,2010, 9:215 -236. 被引量:1
  • 9Mishra J,Zhang Q, Rosson JL, et al. Lipopolysaceharide increases cell surface P-glycoprotein that exhibits diminished activity in intes- tinal epithelial cells [ J ]. Drug Metab Dispos, 2008,36 ( 10 ) : 2145 - 2149. 被引量:1
  • 10Tomita M,Takizawa Y, Kanbayashi A, et al. Suppression of efflux transporters in the intestines of endotoxin-treated rats [ J 1. Int J Pharm ,2012,428 ( 1 - 2) :33 - 38. 被引量:1

引证文献10

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部